Posted by Michael Wonder on 02 Aug 2016
Afatinib dimaleate for patients with advanced squamous cell carcinoma of the lung: additional clinical benefits not there says IQWiG
1 August 2016 - Submitted comparisons for the benefit assessment are unsuitable.
Afatinib dimaleate (Giotrif) has been available since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer with squamous cell histology who have been treated with chemotherapy. In an early benefit assesment, the IQWiG has investigated whether this medicine has advantages over the appropriate comparator therapy.
The IQWiG has concluded there is no evidence of an additional clinical benefit of afatinib dimaleate for these patients.
